Alzheimer's Therapeutics Market Aims to Surpass US$ 7,359.7 Million by 2033 with Tailored Treatments | Future Market Insights, Inc.
26 oct. 2023 09h00 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The estimated value of the worldwide Alzheimer's in 2023 is US$ 3,052.3 million. By 2033, the market for Alzheimer's treatments is predicted to grow at...
Alzheimer’s Therapeutics Market To Reach CAGR of 18.7% By 2032, Says DataHorizzon Research
09 oct. 2023 11h36 HE
|
DataHorizzon Research
Fort Collins, Colorado, Oct. 09, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, the Alzheimer’s therapeutics market was valued at USD 3.8 Billion in 2022 and is expected to reach USD...
Alzheimer’s Therapeutics market is projected to grow at a CAGR of 9.17% by 2032: Visiongain Reports Ltd
19 janv. 2023 11h45 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Alzheimer’s Therapeutics 2022-2032. It includes profiles of Alzheimer’s Therapeutics and Forecasts Market Segment by Drug (Donepezil, Rivastigmine,...
Alzheimer’s Therapeutics market is projected to grow at a CAGR of 9.17% by 2032: Visiongain Reports Ltd
13 déc. 2022 06h46 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Alzheimer’s Therapeutics 2022-2032. It includes profiles of Alzheimer’s Therapeutics and Forecasts Market Segment by Drug (Donepezil, Rivastigmine,...
Alzheimer’s Therapeutics Market Predicted Is Expected to Reach USD 13 Billion by 2031, Says Allied Market Research
06 nov. 2022 18h30 HE
|
Allied Market Research
Portland, OR, Nov. 06, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Alzheimer’s therapeutics market was estimated at $6.1 billion in 2021 and is...
Alzheimer’s Therapeutics Market Is Set to Expand at a CAGR Of 9.3% To reach US$ 6.8 Bn By The Year 2032 : FMI
15 avr. 2022 08h00 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
DUBAI, United Arab Emirates, April 15, 2022 (GLOBE NEWSWIRE) -- Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential...